JP7399880B2 - ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 - Google Patents

ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 Download PDF

Info

Publication number
JP7399880B2
JP7399880B2 JP2020561607A JP2020561607A JP7399880B2 JP 7399880 B2 JP7399880 B2 JP 7399880B2 JP 2020561607 A JP2020561607 A JP 2020561607A JP 2020561607 A JP2020561607 A JP 2020561607A JP 7399880 B2 JP7399880 B2 JP 7399880B2
Authority
JP
Japan
Prior art keywords
amino acid
acid position
domain
binding polypeptide
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561607A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019147973A5 (enExample
JP2021511830A (ja
Inventor
ホワウェイ・チウ
ブライアン・マクネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7399880(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2021511830A publication Critical patent/JP2021511830A/ja
Publication of JPWO2019147973A5 publication Critical patent/JPWO2019147973A5/ja
Priority to JP2023204313A priority Critical patent/JP2024026255A/ja
Application granted granted Critical
Publication of JP7399880B2 publication Critical patent/JP7399880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020561607A 2018-01-26 2019-01-25 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 Active JP7399880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204313A JP2024026255A (ja) 2018-01-26 2023-12-04 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
US62/622,468 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204313A Division JP2024026255A (ja) 2018-01-26 2023-12-04 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Publications (3)

Publication Number Publication Date
JP2021511830A JP2021511830A (ja) 2021-05-13
JPWO2019147973A5 JPWO2019147973A5 (enExample) 2022-02-01
JP7399880B2 true JP7399880B2 (ja) 2023-12-18

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561607A Active JP7399880B2 (ja) 2018-01-26 2019-01-25 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP2023204313A Pending JP2024026255A (ja) 2018-01-26 2023-12-04 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023204313A Pending JP2024026255A (ja) 2018-01-26 2023-12-04 ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Country Status (16)

Country Link
US (1) US20190263934A1 (enExample)
EP (1) EP3743441A1 (enExample)
JP (2) JP7399880B2 (enExample)
KR (2) KR102748986B1 (enExample)
CN (2) CN119350481A (enExample)
AU (2) AU2019212638B2 (enExample)
BR (1) BR112020015006A2 (enExample)
CA (1) CA3089602A1 (enExample)
CO (1) CO2020010269A2 (enExample)
IL (2) IL318916A (enExample)
MX (2) MX2020007882A (enExample)
MY (1) MY203898A (enExample)
PH (1) PH12020551134A1 (enExample)
SG (1) SG11202006905YA (enExample)
TW (1) TW201940512A (enExample)
WO (1) WO2019147973A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542884A (ja) * 2019-07-25 2022-10-07 ジェンザイム・コーポレーション Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2024026255A (ja) * 2018-01-26 2024-02-28 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
EP4149969A1 (en) * 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP4204091A2 (en) * 2020-10-29 2023-07-05 Formycon AG Ace2 fusion proteins and uses thereof
MX2023014100A (es) 2021-05-27 2023-12-11 Sanofi Sa Variante de fc con afinidad aumentada para los receptores de fc y estabilidad termica mejorada.
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
KR20250094703A (ko) 2022-10-25 2025-06-25 아블린쓰 엔.브이. 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
KR20250120344A (ko) 2022-12-05 2025-08-08 사노피 트랜스페린 수용체 결합 단백질
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
JP2011502126A (ja) 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2017534646A (ja) 2014-11-10 2017-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2010068722A1 (en) * 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
US9023996B2 (en) * 2009-12-23 2015-05-05 Synimmune Gmbh Anti-FLT3 antibodies
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
KR102266819B1 (ko) * 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
SI3215528T1 (sl) * 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
KR102777127B1 (ko) * 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
KR102748986B1 (ko) * 2018-01-26 2025-01-02 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2011502126A (ja) 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2017534646A (ja) 2014-11-10 2017-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026255A (ja) * 2018-01-26 2024-02-28 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP2022542884A (ja) * 2019-07-25 2022-10-07 ジェンザイム・コーポレーション Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Also Published As

Publication number Publication date
IL276286A (en) 2020-09-30
IL318916A (en) 2025-04-01
KR20200115568A (ko) 2020-10-07
MX2025009543A (es) 2025-09-02
AU2025204826A1 (en) 2025-07-17
CA3089602A1 (en) 2019-08-01
MX2020007882A (es) 2020-12-03
NZ767453A (en) 2025-03-28
MY203898A (en) 2024-07-23
BR112020015006A2 (pt) 2020-12-29
US20190263934A1 (en) 2019-08-29
CN111788221A (zh) 2020-10-16
IL276286B2 (en) 2025-07-01
TW201940512A (zh) 2019-10-16
PH12020551134A1 (en) 2021-05-31
CN119350481A (zh) 2025-01-24
SG11202006905YA (en) 2020-08-28
EP3743441A1 (en) 2020-12-02
KR20250008975A (ko) 2025-01-16
CO2020010269A2 (es) 2020-12-10
KR102748986B1 (ko) 2025-01-02
AU2019212638B2 (en) 2025-04-03
JP2021511830A (ja) 2021-05-13
AU2019212638A1 (en) 2020-09-17
IL276286B1 (en) 2025-03-01
JP2024026255A (ja) 2024-02-28
RU2020128177A (ru) 2022-02-28
WO2019147973A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
JP7165996B2 (ja) 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
WO2022061236A1 (en) High affinity anti-ige antibodies
WO2021064153A1 (en) Hybrid antibody
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
EP4602075A2 (en) Epidermal growth factor receptor variant iii antibodies
KR20250024825A (ko) 폴리스타틴-fc 융합 단백질
EA040482B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231206

R150 Certificate of patent or registration of utility model

Ref document number: 7399880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150